Literature DB >> 27016655

Failure of primary atovaquone prophylaxis for prevention of toxoplasmosis in hematopoietic cell transplant recipients.

K Gajurel1, C A Gomez1, R Dhakal2, H Vogel3, J G Montoya1,2.   

Abstract

The efficacy of primary prophylaxis with atovaquone in preventing Toxoplasma reactivation and disease in hematopoietic cell transplant (HCT) recipients is unknown. We describe 2 cases of atovaquone prophylaxis failure in pre-HCT Toxoplasma-seropositive (pre-HCTSP) recipients who underwent allogeneic HCT (allo-HCT) and review the literature on atovaquone prophylaxis in HCT recipients.
© 2016 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  zzm321990Toxoplasmazzm321990; atovaquone; hematopoietic cell transplant; preemptive treatment; prophylaxis; toxoplasmosis

Year:  2016        PMID： 27016655     DOI： 10.1111/tid.12532

Source DB:  PubMed          Journal:  Transpl Infect Dis        ISSN： 1398-2273            Impact factor:   2.228


  7 in total

1.  Evolution of resistance in vitro reveals mechanisms of artemisinin activity in Toxoplasma gondii.

Authors:  Alex Rosenberg; Madeline R Luth; Elizabeth A Winzeler; Michael Behnke; L David Sibley
Journal:  Proc Natl Acad Sci U S A       Date:  2019-12-05       Impact factor: 11.205

2.  Missed diagnosis and misdiagnosis of infectious diseases in hematopoietic cell transplant recipients: an autopsy study.

Authors:  Ashrit Multani; Libby S Allard; Tamna Wangjam; R Alejandro Sica; David J Epstein; Andrew R Rezvani; Dora Y Ho
Journal:  Blood Adv       Date:  2019-11-26

3.  Evaluation of Current and Emerging Antimalarial Medicines for Inhibition of Toxoplasma gondii Growth in Vitro.

Authors:  Joshua B Radke; Jeremy N Burrows; Daniel E Goldberg; L David Sibley
Journal:  ACS Infect Dis       Date:  2018-07-25       Impact factor: 5.084

4.  Clinical characteristics and outcomes of toxoplasmosis among transplant recipients at two US academic medical centers.

Authors:  Ruth O Adekunle; Amy Sherman; Jennifer O Spicer; Julia A Messina; Julie M Steinbrink; Mary Elizabeth Sexton; George Marshall Lyon; Aneesh K Mehta; Varun K Phadke; Michael H Woodworth
Journal:  Transpl Infect Dis       Date:  2021-06-01

Review 5.  Drugs in development for toxoplasmosis: advances, challenges, and current status.

Authors:  P Holland Alday; Joseph Stone Doggett
Journal:  Drug Des Devel Ther       Date:  2017-01-25       Impact factor: 4.162

Review 6.  Drug Resistance in Toxoplasma gondii.

Authors:  Mahbobeh Montazeri; Saeed Mehrzadi; Mehdi Sharif; Shahabeddin Sarvi; Asal Tanzifi; Sargis A Aghayan; Ahmad Daryani
Journal:  Front Microbiol       Date:  2018-10-29       Impact factor: 5.640

7.  Bicyclic azetidines target acute and chronic stages of Toxoplasma gondii by inhibiting parasite phenylalanyl t-RNA synthetase.

Authors:  Joshua B Radke; Bruno Melillo; Payal Mittal; Manmohan Sharma; Amit Sharma; Yong Fu; Taher Uddin; Arthur Gonse; Eamon Comer; Stuart L Schreiber; Anil K Gupta; Arnab K Chatterjee; L David Sibley
Journal:  Nat Commun       Date:  2022-01-24       Impact factor: 17.694
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.